166 related articles for article (PubMed ID: 24701255)
1. Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis--cross-sectional study and literature review.
Popescu C; Zofotă S; Bojincă V; Ionescu R
J Med Life; 2013; 6(4):376-82. PubMed ID: 24701255
[TBL] [Abstract][Full Text] [Related]
2. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis.
Inanc N; Dalkilic E; Kamali S; Kasapoglu-Günal E; Elbir Y; Direskeneli H; Inanc M
Clin Rheumatol; 2007 Jan; 26(1):17-23. PubMed ID: 16538391
[TBL] [Abstract][Full Text] [Related]
3. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis.
Candia L; Marquez J; Gonzalez C; Santos AM; Londoño J; Valle R; Zabaleta J; Yaqub Z; Espinoza LR
J Clin Rheumatol; 2006 Oct; 12(5):226-9. PubMed ID: 17023808
[TBL] [Abstract][Full Text] [Related]
4. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation.
Alenius GM; Berglin E; Rantapää Dahlqvist S
Ann Rheum Dis; 2006 Mar; 65(3):398-400. PubMed ID: 16096328
[TBL] [Abstract][Full Text] [Related]
5. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis.
Korendowych E; Owen P; Ravindran J; Carmichael C; McHugh N
Rheumatology (Oxford); 2005 Aug; 44(8):1056-60. PubMed ID: 15901902
[TBL] [Abstract][Full Text] [Related]
6. Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis.
Shibata S; Tada Y; Komine M; Hattori N; Osame S; Kanda N; Watanabe S; Saeki H; Tamaki K
J Dermatol Sci; 2009 Jan; 53(1):34-9. PubMed ID: 18752933
[TBL] [Abstract][Full Text] [Related]
7. Antibodies against cyclic citrullinated peptide in Japanese psoriatic arthritis patients.
Maejima H; Aki R; Watarai A; Shirai K; Hamada Y; Katsuoka K
J Dermatol; 2010 Apr; 37(4):339-45. PubMed ID: 20507403
[TBL] [Abstract][Full Text] [Related]
8. Anti-cyclic citrullinated peptide antibody determination in synovial fluid of psoriatic arthritis.
Spadaro A; Riccieri V; Scrivo R; Alessandri C; Valesini G
Clin Exp Rheumatol; 2007; 25(4):599-604. PubMed ID: 17888217
[TBL] [Abstract][Full Text] [Related]
9. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
Caspi D; Anouk M; Golan I; Paran D; Kaufman I; Wigler I; Levartovsky D; Litinsky I; Elkayam O
Arthritis Rheum; 2006 Feb; 55(1):53-6. PubMed ID: 16463412
[TBL] [Abstract][Full Text] [Related]
10. Are anti-CCP antibodies in psoriatic arthritis patients a biomarker of erosive disease?
Perez-Alamino R; Garcia-Valladares I; Cuchacovich R; Iglesias-Gamarra A; Espinoza LR
Rheumatol Int; 2014 Sep; 34(9):1211-6. PubMed ID: 24515446
[TBL] [Abstract][Full Text] [Related]
11. Antibodies to Cyclic Citrullinated Peptides in Patients With Juvenile Idiopathic Arthritis and Patients With Rheumatoid Arthritis: Shared Expression of the Inherently Autoreactive 9G4 Idiotype.
Peckham H; Cambridge G; Bourke L; Sen D; Radziszewska A; Leandro M; Ioannou Y
Arthritis Rheumatol; 2017 Jul; 69(7):1387-1395. PubMed ID: 28380667
[TBL] [Abstract][Full Text] [Related]
12. Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients.
Payet J; Goulvestre C; Bialé L; Avouac J; Wipff J; Job-Deslandre C; Batteux F; Dougados M; Kahan A; Allanore Y
J Rheumatol; 2014 Dec; 41(12):2395-402. PubMed ID: 25274898
[TBL] [Abstract][Full Text] [Related]
13. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis.
Vander Cruyssen B; Hoffman IE; Zmierczak H; Van den Berghe M; Kruithof E; De Rycke L; Mielants H; Veys EM; Baeten D; De Keyser F
Ann Rheum Dis; 2005 Aug; 64(8):1145-9. PubMed ID: 15695535
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics of psoriatic arthritis with positive rheumatoid factor or anti-cyclic citrullinated peptide antibody].
Dai LY; Gong DD; Zhao JX
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 51(6):1008-1013. PubMed ID: 31848495
[TBL] [Abstract][Full Text] [Related]
15. Antibodies to cyclic citrullinated peptides in psoriatic arthritis.
Bogliolo L; Alpini C; Caporali R; Scirè CA; Moratti R; Montecucco C
J Rheumatol; 2005 Mar; 32(3):511-5. PubMed ID: 15742445
[TBL] [Abstract][Full Text] [Related]
16. Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis.
Tesija-Kuna A; Grazio S; Miler M; Vukasovic I; Peric P; Vrkic N
Clin Rheumatol; 2010 May; 29(5):487-93. PubMed ID: 20069329
[TBL] [Abstract][Full Text] [Related]
17. Role of anti cyclic citrullinated peptide antibodies in erosive disease in patients with rheumatoid arthritis.
Shankar S; Grover R; Handa R
Indian J Med Res; 2006 Dec; 124(6):689-96. PubMed ID: 17287557
[TBL] [Abstract][Full Text] [Related]
18. The significance of rheumatoid factor and anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus.
Popescu C; Zofotă S; Bojincă V; Ionescu R
Rom J Intern Med; 2013; 51(3-4):179-87. PubMed ID: 24620631
[TBL] [Abstract][Full Text] [Related]
19. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
